| Heading: |
Givinostat |
| Question ID: |
1785026 |
| UIN: |
38494 |
| House: |
Commons |
| Date tabled: |
2025-03-14 |
| Asking Member ID: |
5197 |
| Asking Member display name: |
Dr Neil Shastri-Hurst
|
| Asking Member handle: |
drnshastrihurst
|
| Asking Member Twitter reference: |
@drnshastrihurst
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with (a) NHS England and (b) ITF Pharma UK to ensure that NHS Trusts have the necessary resources and guidance to take part in the Early Access Programme for |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-03-26 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Department understands the impact that Duchenne muscular dystrophy has on those living with it and their families, and the urgent need for new treatment options. The National Institute for Health and Care Excellence (NICE) recently published guidance ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |